The use of global profiling in biomarker development for gliomas

Brain Pathology

Volumn 21, Issue 1, 2011, Pages 88-95

  Sulman, Erik P ^a   Aldape, Ken ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

biomarkers; brain tumors; DNA copy number variation; DNA methylation; genomic profiling; glioblastoma; glioma; microarray; predictive markers; prognostic markers

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 2;

CONFERENCE PAPER; DISEASE MARKER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENOMICS; GLIOMA; HIGH THROUGHPUT SCREENING; HUMAN; PREDICTOR VARIABLE; PROGNOSIS;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650029376     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2010.00456.x     Document Type: Conference Paper

References (72)

1. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
3. Allison DB, Cui X, Page GP, Sabripour M, (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65.
4. Baker J, (2007) Genomic Health, Inc. Pharmacogenomics 8: 397-399.
5. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, et al (2005) Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2: 351-356.
6. Bozinov O, Kohler S, Samans B, Benes L, Miller D, Ritter M, et al (2008) Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev 31: 83-89.
7. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E, (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4: e7752.
8. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479.
9. Caskey LS, Fuller GN, Bruner JM, Yung WK, Sawaya RE, Holland EC, Zhang W, (2000) Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 15: 971-981.
10. Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, Dyson NJ, (2001) Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7: 2387-2395.
11. Chari R, Coe BP, Wedseltoft C, Benetti M, Wilson IM, Vucic EA, et al (2008) SIGMA2: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes. BMC Bioinformatics 9: 422.
12. Cheung HC, Baggerly KA, Tsavachidis S, Bachinski LL, Neubauer VL, Nixon TJ, et al (2008) Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 9: 216.
13. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49-57.
14. Czernicki T, Zegarska J, Paczek L, Cukrowska B, Grajkowska W, Zajaczkowska A, et al (2007) Gene expression profile as a prognostic factor in high-grade gliomas. Int J Oncol 30: 55-64.
15. Dai B, Kang SH, Gong W, Liu M, Aldape KD, Sawaya R, Huang S, (2007) Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 26: 6212-6219.
16. Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K, et al (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7: 41.
17. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
18. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
19. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, et al (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25: 1196-1208.
20. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, Van Der Spek P, et al (2005) Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 65: 11335-11344.
21. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, Van Den Bent MJ, et al (2007) Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 67: 5635-5642.
22. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, et al (1999) Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59: 4228-4232.
23. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7: 278.
24. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, et al (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63: 6613-6625.
25. Gravendeel LA, Kouwenhoven MC, Gevaert O, De Rooi JJ, Stubbs AP, Duijm JE, et al (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065-9072.
26. Hagerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Hartman M, et al (2008) Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Neuro Oncol 10: 2-9.
27. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
28. Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H, (2000) Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res 60: 6868-6874.
29. Huang H, Okamoto Y, Yokoo H, Heppner FL, Vital A, Fevre-Montange M, et al (2004) Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 23: 6012-6022.
30. Khatua S, Peterson KM, Brown KM, Lawlor C, Santi MR, LaFleur B, et al (2003) Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63: 1865-1870.
31. Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, Trent JM, et al (2002) Identification of combination gene sets for glioma classification. Mol Cancer Ther 1: 1229-1236.
32. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Quezado M, et al (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69: 2091-2099.
33. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819.
34. Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, et al (2006) A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66: 10815-10823.
35. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, et al (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66: 3593-3602.
36. Mardis ER, (2008) Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9: 387-402.
37. Mardis ER, (2008) The impact of next-generation sequencing technology on genetics. Trends Genet 24: 133-141.
38. Margareto J, Leis O, Larrarte E, Idoate MA, Carrasco A, Lafuente JV, (2007) Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. J Mol Neurosci 32: 53-63.
39. McDonald KL, O'Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, et al (2007) IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66: 405-417.
40. Mukasa A, Ueki K, Matsumoto S, Tsutsumi S, Nishikawa R, Fujimaki T, et al (2002) Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21: 3961-3968.
41. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T, et al (2004) Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 14: 34-42.
42. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678-1686.
43. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
44. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607.
45. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO, (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11: 2258-2264.
46. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
47. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
48. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP, (1994) Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 91: 5022-5026.
49. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, et al (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11: 3326-3334.
50. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, et al (2006) Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935-3941.
51. Persson O, Krogh M, Saal LH, Englund E, Liu J, Parsons R, et al (2007) Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol 85: 11-24.
52. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
53. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
54. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, Sawaya R, (2004) Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 10: 212-221.
55. Reddy SP, Britto R, Vinnakota K, Aparna H, Sreepathi HK, Thota B, et al (2008) Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 14: 2978-2987.
56. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, et al (2001) Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61: 6885-6891.
57. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12: 116-121.
58. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
59. Ruano Y, Mollejo M, Camacho FI, Rodriguez de Lope A, Fiano C, Ribalta T, et al (2008) Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme. Cancer 112: 1575-1584.
60. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, et al (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60: 6617-6622.
61. Schena M, Shalon D, Davis RW, Brown PO, (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470.
62. Scrideli CA, Carlotti CG, Jr, Okamoto OK, Andrade VS, Cortez MA, Motta FJ, et al (2008) Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88: 281-291.
63. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, et al (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22: 4918-4923. (Pubitemid 36981282)
64. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al (2005) Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 24: 7073-7083.
65. Tanwar MK, Gilbert MR, Holland EC, (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62: 4364-4368.
66. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG, (2002) FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62: 4773-4780.
67. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, et al (2006) Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119: 792-800.
68. Van De Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
69. Van Den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, et al (2003) Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163: 1033-1043.
70. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
71. Watson MA, Perry A, Budhraja V, Hicks C, Shannon WD, Rich KM, (2001) Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 61: 1825-1829.
72. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.